Amylyx Pharmaceuticals (AMLX) EBIT (2021 - 2026)

Amylyx Pharmaceuticals' EBIT history runs 6 years deep, the most recent figure standing at -$43.8 million for Q1 2026.

• In Q1 2026, EBIT fell 15.81% year-over-year to -$43.8 million; the TTM figure through Mar 2026 stood at -$36.4 million (down 274.16% YoY), while the FY2025 annual figure was -$30.4 million, up 52.11% from the prior year.
• EBIT was -$43.8 million for Q1 2026 at Amylyx Pharmaceuticals, down from $86.3 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $210.6 million in Q4 2024 to a low of -$122.1 million in Q1 2024.
• Historically, EBIT has averaged -$17.7 million across 5 years, with a median of -$42.9 million in 2025.
• Biggest YoY gain for EBIT was 10790.8% in 2024; the steepest drop was 5848.86% in 2024.
• A 5-year view of EBIT shows it stood at -$44.6 million in 2022, then surged by 104.34% to $1.9 million in 2023, then jumped by 10790.8% to $210.6 million in 2024, then slumped by 59.03% to $86.3 million in 2025, then tumbled by 150.73% to -$43.8 million in 2026.
• The last three EBIT figures came in at -$43.8 million (Q1 2026), $86.3 million (Q4 2025), and -$36.0 million (Q3 2025), per Business Quant data.